| ²é¿´: 931 | »Ø¸´: 2 | ||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||
chenlinanaͳæ (³õÈëÎÄ̳)
|
[ÇóÖú]
ÇëÎʸßÊÖÕâ¾ä»°ÖÐtreat and extend regimenÓ¦¸ÃÔõô·Ò룿
|
|
|
To evaluate the visual outcome, number of injections, and direct medical cost of a "treat and extend regimen (TER) in managing neovascular age-related macular degeneration (nAMD) with intravitreal ranibizumab. ÇëÎʸßÊÖÕâ¾ä»°ÖÐtreat and extend regimenÓ¦¸ÃÔõô·Ò룿 |
» ²ÂÄãϲ»¶
Ò»Ö¾Ô¸»ª¶«Ê¦·¶ÉúÎïѧ326·Ö£¬Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
071000ÉúÎïѧµ÷¼ÁÇóÖú
ÒѾÓÐ11È˻ظ´
»¯Ñ§¹¤³ÌÓë¼¼Êõ324µ÷¼Á
ÒѾÓÐ16È˻ظ´
298Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
282£¬Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
¿¼Ñе÷¼Á
ÒѾÓÐ19È˻ظ´
308Çóµ÷¼Á
ÒѾÓÐ20È˻ظ´
ÖпÆÔº×Ü·Ö315Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Çóµ÷¼Á ²ÄÁÏÓ빤³Ì 324·Ö ר˶
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸¿ó´ó£¬²ÄÁϹ¤³Ìר˶314·Ö£¬0856¿Éµ÷¶¼¿ÉÒÔ
ÒѾÓÐ12È˻ظ´

xux730
Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 86
- Ó¦Öú: 1719 (½²Ê¦)
- ½ð±Ò: 10740.4
- É¢½ð: 50
- ºì»¨: 43
- Ìû×Ó: 2947
- ÔÚÏß: 336.5Сʱ
- ³æºÅ: 1374299
- ×¢²á: 2011-08-20
- רҵ: ϸ°ûÖÜÆÚÓëµ÷¿Ø
3Â¥2014-08-01 02:56:21
RXMCDM
°æÖ÷ (ÎÄ̳¾«Ó¢)
- ·ÒëEPI: 530
- Ó¦Öú: 401 (˶ʿ)
- ¹ó±ö: 1.908
- ½ð±Ò: 38947.6
- É¢½ð: 4908
- ºì»¨: 88
- ɳ·¢: 4
- Ìû×Ó: 11453
- ÔÚÏß: 1355.6Сʱ
- ³æºÅ: 2739168
- ×¢²á: 2013-10-20
- ÐÔ±ð: GG
- רҵ: Ò»°ã¹ÜÀíÀíÂÛÓëÑо¿·½·¨ÂÛ
- ¹ÜϽ: ÂÛÎÄ·Òë
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
|
ÕÒµ½ÄÜ˵Ã÷Õâ¸ö´ÊµÄÎÄ×ÖÈçÏ£¬¾õµÃ¿ÉÒÔÃãÇ¿·Îª¡¡¡¡ÖÎÁƼÁÁ¿¼°ÖÎÁƺóµÍƵ¸øÒ©¡¡¡¡¹©Äã²Î¿¼£¡ TREAT AND EXTEND¡± DOSING OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR TYPE 3 NEOVASCULARIZATION/RETINAL ANGIOMATOUS PROLIFERATION Purpose: The purpose of this study was to analyze long-term outcomes for the treatment of type 3 neovascularization/retinal angiomatous proliferation using a ¡°Treat and Extend¡± dosing regimen for antivascular endothelial growth factor therapy. Methods: This was a retrospective analysis of visual acuity and optical coherence tomography data of 11 eyes of 10 consecutive patients with newly diagnosed type 3 neovascularization/retinal angiomatous proliferation treated with intravitreal bevacizumab and/or ranibizumab with at least a 12-month follow-up. Three monthly injections were followed by continued treatment at intervals increasing by 2 weeks per visit, to a maximum of 10 weeks, unless clinical or optical coherence tomography evidence of persistent or recurrent fluid was present, in which case, the interval was shortened. |

2Â¥2014-08-01 00:17:24













»Ø¸´´ËÂ¥